PTSM: Pharmaceutical Technology Sourcing and Management
The pen injectors will be produced at Catalent’s Brussels, Belgium facility.
Catalent Pharma Solutions and Palatin Technologies have reached a commercial supply agreement to support the launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD), Catalent said in a June 30, 2016 press announcement. Bremelanotide is a subcutaneous injectable peptide melanocortin receptor agonist and is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. The bremelanotide pen injectors will be produced at Catalent's 265,000-sq.-ft. Brussels, Belgium facility, Catalent noted. Phase III trials of bremelanotide are currently ongoing, with launch anticipated in 2018.
Source:
about 10 years ago
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017about 10 years ago
Supply Chain Partner Scrutiny Moves Beyond GMPsabout 10 years ago
Chiral Advances Demonstrate Promise for API Synthesisabout 10 years ago
NIST Issues mAb Reference Standardabout 10 years ago
EMA Suspends Drugs Due to Flawed Bioequivalence Studiesabout 10 years ago
CordenPharma Expands into Oligonucleotide APIsabout 10 years ago
Shimadzu System Combines HPLC and UHPLC Methodsabout 10 years ago
Zenith Appoints Serialization Directorabout 10 years ago
CSafe Opens Facility in Puerto Rico
